Analysis of Revenues
Paying user area
Try for free
Biogen Inc. pages available for free this week:
- Balance Sheet: Assets
- Common-Size Income Statement
- Common-Size Balance Sheet: Assets
- Analysis of Liquidity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Common Stock Valuation Ratios
- Enterprise Value to FCFF (EV/FCFF)
- Present Value of Free Cash Flow to Equity (FCFE)
- Operating Profit Margin since 2005
- Debt to Equity since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Biogen Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Revenues as Reported
Biogen Inc., income statement, revenues
US$ in thousands
| 12 months ended: | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Multiple Sclerosis (MS) | |||||||||||
| Spinal Muscular Atrophy | |||||||||||
| Alzheimer’s disease | |||||||||||
| Biosimilars | |||||||||||
| Other | |||||||||||
| Hemophilia | |||||||||||
| Product revenues |
Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).
- Multiple Sclerosis (MS) Revenue Trend
- The revenue from Multiple Sclerosis (MS) products shows a consistent decline over the observed period. Starting at approximately 8.98 billion USD in 2017, it decreased gradually each year to about 6.10 billion USD by 2021. This marks a significant reduction, especially notable between 2020 and 2021.
- Spinal Muscular Atrophy Revenue Trend
- The revenue for Spinal Muscular Atrophy exhibits a strong growth pattern from 2017 through 2019, increasing from approximately 884 million USD to 2.10 billion USD. Although there was a slight dip in 2020 and a further decrease in 2021, the values remained considerably higher than the initial 2017 figure, indicating an overall positive trend despite recent declines.
- Alzheimer’s Disease Revenue
- Revenue figures for Alzheimer’s disease are absent until 2021, where a minimal amount of 3 thousand USD is recorded, suggesting either the recent introduction of these products or nascent sales within this segment.
- Biosimilars Revenue Trend
- Biosimilars revenue demonstrates steady growth across all years, rising from approximately 380 million USD in 2017 to 831 million USD in 2021. This consistent upward trajectory reflects increasing market penetration or sales volume in this segment.
- Other Revenue Trend
- The 'Other' category experiences a steady decline throughout the period, decreasing from around 40 million USD in 2017 to 11 million USD in 2021, indicating diminishing contributions from miscellaneous product lines or services.
- Hemophilia Revenue
- Revenue from Hemophilia is only reported in 2017 at 74 million USD, with no data available for subsequent years, suggesting discontinuation, divestment, or data unavailability for this product line post-2017.
- Total Product Revenues
- The overall product revenue follows an upward trajectory from 2017 through 2019, increasing from approximately 10.35 billion USD to 11.38 billion USD. However, a decline is observed in 2020 and a more pronounced decrease in 2021, dropping to about 8.85 billion USD. This downturn is primarily influenced by the substantial reduction in Multiple Sclerosis revenue and to some extent by the decreases in other categories.